<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5070">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176955</url>
  </required_header>
  <id_info>
    <org_study_id>8982</org_study_id>
    <nct_id>NCT01176955</nct_id>
  </id_info>
  <brief_title>A Novel Method to Improve Acne Outcomes</brief_title>
  <official_title>A Novel Method for Improving Acne Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest School of Medicine</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator-blinded, prospective study of 20 subjects aged 13 through 18 with
      mild to moderate acne. Study subjects will be randomized to an internet survey group, in
      which an email link for a survey ascertaining the status of the subject's acne is sent
      weekly, or to a control group. All study subjects will use benzoyl peroxide 5% gel, and
      adherence and clinical improvement will be monitored over 12 weeks. The investigators
      hypothesis is that subjects in the internet survey group will have improved adherence to the
      study medication and clinical outcomes, because the weekly survey will remind subjects to
      use their medication.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adherence to Study Medication</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adherence will be objectively measured with the Medication Event Monitoring System (MEMS) cap and the percentage of prescribed doses taken will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change (Dynamic Assessment) in the Acne Global Assessment From Baseline to End of Study.</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Acne Global Assessment is measured by a study investigator and is an overall assessment of the subject's acne severity, on a 0 (clear) to 5 (very severe) scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change (Dynamic Assessment) From Baseline to End of Treatment in Lesion Counts.</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Both inflammatory (papules, pustules and nodules) and non-inflammatory (open and closed comedones) acne lesions will be counted by a study investigator. Percentage change from baseline to the final study visit will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Measured Adherence by the MEMS Cap in Relation to the Patient Reported Adherence Via the Internet Survey.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study subjects' self-reported adherence (in the intervention group, via the weekly internet survey) will be compared to objectively measured adherence via MEMS caps.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Measured Adherence by the MEMS Cap in Relation to the Change (Dynamic Assessment) in the Acne Global Assessment.</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>All study subjects' objective adherence will be compared to clinical improvement as measured by the Acne Global Assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Internet survey</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive standard-of-care treatment with the study medication, without internet surveys.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Internet survey</intervention_name>
    <description>A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.</description>
    <arm_group_label>Internet survey</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl peroxide 5% gel</intervention_name>
    <description>Topical benzoyl peroxide 5% gel, to be used once daily to the face.</description>
    <arm_group_label>Internet survey</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female 13 to 18 years of age with a diagnosis of mild to moderate acne
             vulgaris by a dermatologist.

          -  written consent of participation must be given by parent or guardian and child.

        Exclusion Criteria:

          -  Age less than 13 or greater than 18 years of age.

          -  Known allergy or sensitivity to topical benzoyl peroxide gel in the subject.

          -  Inability to complete all study-related visits.

          -  Introduction of any other prescription medication, topical or systemic, for acne
             vulgaris while participating in the study.

          -  Subjects may not use topical retinoids or other benzoyl peroxide products, including
             ProactivÂ® or topical prescription medications while enrolled in the study.

          -  Women that are actively trying to become pregnant or wish to become pregnant during
             the time frame the study is to take place will be excluded.

          -  Subjects will be carefully selected for this study and only those deemed appropriate
             for treatment with benzoyl peroxide will be placed on this medication.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven R Feldman, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Wake Forest University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences, Department of Dermatology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <lastchanged_date>November 9, 2011</lastchanged_date>
  <firstreceived_date>August 5, 2010</firstreceived_date>
  <firstreceived_results_date>July 1, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wake Forest University</investigator_affiliation>
    <investigator_full_name>Steven R. Feldman</investigator_full_name>
    <investigator_title>Professor of Dermatology</investigator_title>
  </responsible_party>
  <keyword>Acne</keyword>
  <keyword>Acne vulgaris</keyword>
  <keyword>Adherence</keyword>
  <keyword>Compliance</keyword>
  <keyword>MEMS</keyword>
  <keyword>Benzoyl peroxide</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Internet Survey</title>
          <description>Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Subjects will receive standard-of-care treatment with the study medication, without internet surveys. Standard-of-care will mean patients are directed to take the medication daily and return for visits at 6 and 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Internet Survey</title>
          <description>Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Subjects will receive standard-of-care treatment with the study medication, without internet surveys. Standard-of-care will mean patients are directed to take the medication daily and return for visits at 6 and 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="15.3" spread="1.49"/>
                <measurement group_id="B2" value="15.5" spread="2.22"/>
                <measurement group_id="B3" value="15.4" spread="1.85"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>The Change (Dynamic Assessment) in the Acne Global Assessment From Baseline to End of Study.</title>
        <description>Acne Global Assessment is measured by a study investigator and is an overall assessment of the subject's acne severity, on a 0 (clear) to 5 (very severe) scale.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Internet Survey</title>
            <description>Patients received a weekly Internet survey to report on the status of their acne.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Patients received standard-of-care therapy without weekly Internet surveys.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Change (Dynamic Assessment) in the Acne Global Assessment From Baseline to End of Study.</title>
            <description>Acne Global Assessment is measured by a study investigator and is an overall assessment of the subject's acne severity, on a 0 (clear) to 5 (very severe) scale.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-0.71" spread="0.76"/>
                  <measurement group_id="O2" value="-0.25" spread="0.46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change (Dynamic Assessment) From Baseline to End of Treatment in Lesion Counts.</title>
        <description>Both inflammatory (papules, pustules and nodules) and non-inflammatory (open and closed comedones) acne lesions will be counted by a study investigator. Percentage change from baseline to the final study visit will be calculated.</description>
        <time_frame>Baseline to 12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Internet Survey</title>
            <description>Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects will receive standard-of-care treatment with the study medication, without internet surveys. Standard-of-care will mean patients are directed to take the medication daily and return for visits at 6 and 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>The Change (Dynamic Assessment) From Baseline to End of Treatment in Lesion Counts.</title>
            <description>Both inflammatory (papules, pustules and nodules) and non-inflammatory (open and closed comedones) acne lesions will be counted by a study investigator. Percentage change from baseline to the final study visit will be calculated.</description>
            <units>percent change in lesion count</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="-36" spread="37"/>
                  <measurement group_id="O2" value="-8" spread="65"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Measured Adherence by the MEMS Cap in Relation to the Patient Reported Adherence Via the Internet Survey.</title>
        <description>Study subjects' self-reported adherence (in the intervention group, via the weekly internet survey) will be compared to objectively measured adherence via MEMS caps.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Measured Adherence by the MEMS Cap in Relation to the Change (Dynamic Assessment) in the Acne Global Assessment.</title>
        <description>All study subjects' objective adherence will be compared to clinical improvement as measured by the Acne Global Assessment.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adherence to Study Medication</title>
        <description>Adherence will be objectively measured with the Medication Event Monitoring System (MEMS) cap and the percentage of prescribed doses taken will be reported.</description>
        <time_frame>12 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Internet Survey</title>
            <description>Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Subjects will receive standard-of-care treatment with the study medication, without internet surveys. Standard-of-care will mean patients are directed to take the medication daily and return for visits at 6 and 12 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                  <measurement group_id="O2" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adherence to Study Medication</title>
            <description>Adherence will be objectively measured with the Medication Event Monitoring System (MEMS) cap and the percentage of prescribed doses taken will be reported.</description>
            <units>Percent of prescribed doses taken</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="74" lower_limit="58" upper_limit="132"/>
                  <measurement group_id="O2" value="32" lower_limit="4" upper_limit="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Internet Survey</title>
          <description>Subjects will receive a weekly email link to complete an internet survey about their acne and use of the study medication.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Subjects will receive standard-of-care treatment with the study medication, without internet surveys. Standard-of-care will mean patients are directed to take the medication daily and return for visits at 6 and 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brad Yentzer</name_or_title>
      <organization>Wake Forest Baptist Medical Center</organization>
      <phone>336-716-4735</phone>
      <email>byentzer@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
